The most useful question to ask an insurer is not “do you cover neuropathy testing.” It is “what documentation would support medical necessity for this specific test, for this specific suspected cause, in my case.” Coverage decisions turn on whether the record shows a clinical reason for the request, and neuropathy is a category rather than a diagnosis, so a chart that names only the category gives a reviewer very little to work with.
Key takeaways
- Ask about documentation and medical necessity, not about coverage in the abstract.
- Ask whether the request is being made for diagnosis or for monitoring, because plans often handle those differently.
- VNG is a diagnostic test of inner-ear balance function. It does not treat neuropathy, and it should not be described to a plan as though it does.
- Qutenza [Capsaicin 8% Patch] is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet [1]. Use for any other driver is off-label and must be documented as such.
- Orthobiologic injections such as PRP and BMAC are not FDA-approved for neuropathy. Plans generally do not cover them.
- We do not publish fees. They are discussed directly with the practice during planning.
Start with the purpose of the test, not the symptom
Most coverage conversations go sideways in the first sentence. The caller describes symptoms, the representative describes a policy, and nobody establishes what the test is meant to determine.
A clearer opening is to state the purpose: this study is being ordered to confirm or exclude a specific suspected cause of nerve symptoms. That framing is what a reviewer is looking for, and it is also what a good work-up produces anyway.
Questions worth asking word for word
- What documentation would support medical necessity for this test in my case?
- Does the answer change if the study is diagnostic rather than for monitoring?
- Is prior authorization required, and who submits it?
- If this is denied, what specifically would need to be added for an appeal?
Write the answers down with the date and the representative name. Appeals usually fail on missing documentation, not on disagreement about medicine.
Coverage questions change with the driver
A request tied to a suspected metabolic cause reads differently from one tied to a suspected nutritional, toxic, autoimmune or structural cause. That is not a billing trick, it is what an honest work-up looks like when the clinician has an actual hypothesis.
At Regenerve the sequence is the same regardless of insurer: identify the likely driver, choose the test that confirms or excludes it, then document why. The coverage conversation is easier because the clinical reasoning already exists.
Testing: what to separate before you call
Electrodiagnostic testing (EMG/NCS)
Electrodiagnostic testing is performed on site at Regenerve and measures conduction in the larger nerve fibers. If your symptoms are burning and temperature change rather than numbness and weakness, ask whether the order addresses large fibers, small fibers or both, because that distinction can determine which benefit category applies.
VNG balance testing
Videonystagmography is a diagnostic test of inner-ear balance function. It is used to work up unsteadiness and falls risk, and it does not treat neuropathy or anything else. When you call, ask how your plan handles vestibular diagnostics, which is a separate question from nerve testing. More detail is on our VNG balance testing page.
Treatments: where the coverage questions get specific
Qutenza (capsaicin 8% topical system)
Qutenza is FDA-approved in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet [1]. Applied to any other neuropathy driver, it is off-label, and the record should say so rather than blur the indication.
Two other label facts matter for planning. It is administered only by a physician or health care professional and is never dispensed for home use, and it is not repeated more frequently than every three months [1]. Our Qutenza page covers how the application visit works.
Orthobiologic injections (PRP and BMAC)
Plans generally do not cover them.
If this is under discussion, ask for that policy language in writing before scheduling anything, and expect the answer to be restrictive.
In-clinic light and infrared therapies
Class 4 photobiomodulation, class 3B cold laser and whole-body infrared are delivered in clinic as components of a plan rather than as one-time procedures. Ask which benefit category your plan assigns to office-based therapy and what documentation it expects per session type.
What we will and will not tell you about cost
We do not publish fees on this site. What a given patient owes depends on the plan, the benefits, and what the visit actually includes, and a posted number would be wrong for most people reading it.
What we will do is tell you directly, before scheduling, what a plan involves and what it costs in your situation. That conversation happens with the practice during planning.
Frequently asked questions
What should I ask my insurer before neuropathy testing?
Ask what documentation supports medical necessity for the specific test in your case, not whether neuropathy is covered in general. Then ask whether the answer differs for a diagnostic study versus repeat monitoring, because plans often treat those differently. Knowing which services are on the table first makes that call shorter, so review what we actually provide before you dial.
Why does my chart need to name a driver instead of just saying neuropathy?
Neuropathy is a category rather than a diagnosis, so a request that names only the category gives a reviewer nothing to evaluate against. When the record states the suspected driver and the test is tied to confirming or excluding it, the clinical reasoning is visible. See how the Regenerve protocol sequences testing.
Is coverage different for small-fiber evaluation than for EMG?
It can be. Electrodiagnostic testing measures the larger nerve fibers, so when your symptoms point at the small fibers a different assessment is needed and your plan may treat it under a different benefit category. Ask which fiber type the order addresses. See small fiber neuropathy symptoms and testing.
How do I find out what a visit will cost me?
We do not publish fees, because what applies to you depends on your plan, your benefits and what the visit actually includes. Fees are discussed directly with the practice during planning, before anything is scheduled. Reach us through the Regenerve contact page.
Start with the Nerve Damage Score
The entry point at Regenerve is the free five-question Nerve Damage Score. It takes a few minutes, and it tells us which driver to look at first so your visit starts with a plan instead of a guess.
Take the free Nerve Damage Score assessment, then bring the result to a physician-led visit at Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. We see patients from the St. Louis region, Missouri and Illinois.
Sources
- U.S. Food and Drug Administration. QUTENZA (capsaicin) topical system — Highlights of Prescribing Information, revised 07/2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022395s024lbl.pdf — referenced for the approved indications in adults (postherpetic neuralgia and diabetic peripheral neuropathy of the feet), for administration by a physician or health care professional only, and for repeat application not more frequently than every three months.